Obesity is associated with blunted β-adrenoreceptor (β-AR)-mediated lipolysis and lipid oxidation in adipose tissue, but the mechanisms linking nutrient overload to catecholamine resistance are poorly understood. We report that targeted disruption of TGF-β superfamily receptor ALK7 alleviates diet-induced catecholamine resistance in adipose tissue, thereby reducing obesity in mice. Global and fat-specific Alk7 knock-out enhanced adipose β-AR expression, β-adrenergic signaling, mitochondrial biogenesis, lipid oxidation, and lipolysis under a high fat diet, leading to elevated energy expenditure, decreased fat mass, and resistance to diet-induced obesity. Conversely, activation of ALK7 reduced β-AR-mediated signaling and lipolysis cell-autonomously in both mouse and human adipocytes. Acute inhibition of ALK7 in adult mice by a chemical-genetic approach reduced diet-induced weight gain, fat accumulation, and adipocyte size, and enhanced adipocyte lipolysis and β-adrenergic signaling. We propose that ALK7 signaling contributes to diet-induced catecholamine resistance in adipose tissue, and suggest that ALK7 inhibitors may have therapeutic value in human obesity.https://doi.org/10.7554/eLife.03245.001
Adrenaline and noradrenaline are two hormones that trigger the burst of energy and increase in heart rate and blood pressure that are needed for the ‘fight-or-flight’ response. Both belong to a group of chemicals called catecholamines. These chemicals bind to cells carrying proteins called adrenoceptors on their surface and stimulate the breakdown of fat, which releases energy. However, when nutrients are plentiful, fat cells become resistant to catecholamines and instead store fat so it can be used for energy if food becomes scarce. In the industrialized world where food is easily and constantly accessible, this resistance can cause an unhealthy increase in body fat and result in obesity.
Increasing fat metabolism by making fat cells more able to respond to catecholamines is an attractive strategy for combating obesity. Indeed, drugs that mimic the effect of catecholamines on an adrenoceptor found in mice reduce obesity caused by over-eating. However, these drugs are ineffective in humans and can cause harmful side effects to the cardiovascular system, including high blood pressure and an increased heart rate. Devising a strategy that specifically targets catecholamine resistance in fat cells is therefore desirable.
A protein called ALK7 is a cell surface receptor that is predominantly found in fat cells and tissues involved in controlling the metabolism. Mice with a mutation in ALK7 that stops this protein from working properly accumulate less fat than mice with a functional version of the protein, but it is not known why. To understand ALK7's involvement in fat metabolism, Guo et al. created mice whose fat cells lack ALK7, but whose other cells all produce ALK7 as normal. When fed a diet rich in fat, these mice are leaner than regular mice and they burn more energy.
The metabolic responses seen in ALK7 mutant mice are very similar to those seen in mice treated with drugs targeting adrenoceptors, suggesting that there may be a link between ALK7 and catecholamine resistance. Indeed, Guo et al. demonstrate that fat cells lacking ALK7 have an increased sensitivity to catecholamines when the mice are on a high fat diet, which decreases the amount of fat the mice accumulate. Conversely, increasing the activity of ALK7 reduces the ability of the cells to respond to catecholamines, and they accumulate more fat.
Guo et al. also generated a second line of mice carrying a mutation in ALK7 that does not affect its function, but renders it sensitive to inhibition by a custom-made chemical. When these animals were on a high-fat diet, administering the chemical made the mice leaner, suggesting that inhibiting the ALK7 receptor can prevent obesity in adult animals.
Guo et al. also performed experiments in human fat cells, which showed that the ALK7 receptor works in a similar way in human cells as it does in mice. As ALK7 is largely specific for fat cells and is not known to affect the cardiovascular system, drugs that inhibit ALK7 could potentially safely suppress catecholamine resistance and reduce human obesity.https://doi.org/10.7554/eLife.03245.002
Agonists of β3-adrenoceptors (β3-AR) are effective anti-obesity agents in rodents due to their ability to stimulate lipolysis and lipid oxidation in adipose tissue (Arch, 2011). However, efforts to develop similar compounds in humans stalled when it became clear that the pharmacology of rodent and human β3-AR differed and lipolysis in human adipocytes was mainly mediated by classical β1- and β2-AR, which can also induce hypertension, tachycardia, and other undesired complications (Arch, 2011). Alternative strategies to enhance catecholamine sensitivity and β-adrenergic signaling selectively in adipose tissue may be effective in combating obesity, but remain unproven. In both humans and rodents, obesity is associated with blunted β-AR-mediated lipolysis and lipid oxidation in adipose tissue (Reynisdottir et al., 1994; Arner, 1999; Jocken et al., 2008), but the mechanisms linking nutrient overload to catecholamine resistance remain poorly understood.
ALK7 is a receptor for a subset of ligands from the TGF-β superfamily, including Nodal, activin B, and GDF-3 (Rydén et al., 1996; Reissmann et al., 2001; Tsuchida et al., 2004; Andersson et al., 2008). ALK7 is not necessary for mouse embryogenesis (Jörnvall et al., 2004), suggesting alternative functions in postnatal development and adult physiology. ALK7 is highly expressed in rodent and human adipose tissue (Kang and Reddi, 1996; Andersson et al., 2008; Carlsson et al., 2009; Murakami et al., 2012), as well as in a few other tissues implicated in metabolic regulation, such as pancreatic islets (Bertolino et al., 2008) and the arcuate nucleus of the hypothalamus (Sandoval-Guzmán et al., 2012). Mice lacking ALK7 show reduced fat accumulation after a high fat diet (Andersson et al., 2008) and in a polygenic model of obesity (Yogosawa et al., 2013), but the mechanisms underlying the effects of ALK7 signaling on diet-induced obesity are not understood. Pancreatic islets from Alk7 knock-out mice show enhanced glucose-stimulated insulin secretion (Bertolino et al., 2008), a phenotype that is also present in islets from mutant mice lacking the ALK7 ligand activin B (Wu et al., 2014). Moreover, the arcuate nucleus of Alk7 knock-out mice shows reduced expression of Npy mRNA and lower numbers of Npy-expressing neurons compared to wild type controls (Sandoval-Guzmán et al., 2012). It has therefore been unclear whether ALK7 affects fat accumulation cell-autonomously in adipose tissue or through other sites, and whether its effects on adult physiology are developmental or homeostatic, via acute regulation of adult cell function.
In this study, we developed a conditional knock-out mouse lacking ALK7 in adipose tissue and a knock-in mouse model carrying an analogue-sensitive kinase allele (ASKA) of ALK7, which can be specifically inhibited by administration of ATP competitive inhibitors. Using these animals, as well as cell culture models, we have established that ALK7 functions cell-autonomously and acutely in adult adipocytes to control energy expenditure and fat accumulation by suppressing adipocyte mitochondrial biogenesis, fatty acid oxidation, and β-AR mediated-lipolysis. Importantly, we found that ALK7 signaling negatively regulates adipocyte β-AR expression and β-adrenergic signaling during a high fat diet, providing a link between nutrient overload and catecholamine resistance in adipose tissue.
In order to dissect the cell-autonomous functions of ALK7 in specific tissues, we generated a conditional knock-out allele of the mouse Alk7 gene (also known as Acvr1c) with loxP sites flanking exons 5 and 6, encoding essential regions of the ALK7 kinase domain (Figure 1—figure supplement 1). Gene deletion in adipose tissue was achieved by crossing Alk7fx mice with Ap2CRE mice (He et al., 2003). Although Ap2CRE has also been reported to be expressed in adipose tissue macrophages (Lee et al., 2013), Alk7 mRNA expression could only be detected in the adipocyte fraction of adipose tissue but not in the stromal-vascular fraction (containing macrophages) or in spleen (Figure 1—figure supplement 2A–D). Expression of Alk7 mRNA was reduced by 60% in the adipose tissue of Alk7fx/fx::Ap2CRE mice, while a 98% reduction was achieved in Alk7fx/−::Ap2CRE mice (i.e., compound heterozygotes carrying floxed and knock-out Alk7 alleles) (Figure 1—figure supplement 3A,B). No change in Alk7 mRNA expression was observed in the pancreas or brain (Figure 1—figure supplement 2B). Both lines of fat-specific Alk7 mutant mice showed significantly reduced weight gain during 12 weeks on a high fat diet compared to controls (Figure 1A,B). In contrast, weight gain in Alk7fx/fx::NestinCRE mice, lacking ALK7 expression in the nervous system (Figure 1—figure supplement 3C), did not differ from controls (Figure 1C). Diet-induced fat accumulation, as measured by epididymal and retroperitoneal fat depot weight (Figure 1D–F), magnetic resonance imaging (MRI) of total fat mass (Figure 1G,H), and adipocyte cell size (Figure 1I,J), was also significantly reduced in fat-specific Alk7 mutant mice compared to controls. In contrast, fat depots of nervous system-specific Alk7 mutant mice were not different from controls (Figure 1K). In agreement with reduced diet-induced obesity, serum leptin levels were also lower after a high fat diet in both global and fat-specific Alk7 knock-out mice (Figure 2A,B). However, fed serum insulin levels remained unchanged in fat-specific and brain-specific Alk7 knock-out mice (Figure 2C,D), suggesting unaltered peripheral insulin sensitivity. In addition, glucose and insulin tolerance tests performed in fat-specific Alk7 mutant mice and controls indicated normal glucose and insulin responses in the mutants (Figure 2E–H). Obesity has been associated with a state of inflammation in adipose tissue in which resident macrophages play important roles (Hotamisligil, 2006; Fujisaka et al., 2009). Following 8 weeks of a high fat diet, adipose tissue of global and fat-specific Alk7 knock-out mice showed decreased expression of markers of pro-inflammatory M1 macrophages, such as TNF1α, IL-12b, and Itgax (Figure 2I,J), but increased expression of Mgl2, a marker of M2 macrophages, the major resident macrophages involved in remodeling and repair that are normally present in adipose tissue from lean mice (Figure 2K,L). This profile is in agreement with reduced adipose tissue inflammation and protection against diet-induced obesity. Together, these results indicate that ALK7 functions cell-autonomously in adipose tissue to regulate fat accumulation during nutrient overload.
The reduced obesity in Alk7 knock-out mice after a high fat diet could be a result of lower calorie intake or higher energy expenditure. Both global knock-out and fat-specific Alk7 mutant mice displayed increased energy expenditure (Figure 3A,B) and oxygen consumption (Figure 3C,D) after a high fat diet compared to controls. Food intake remained unchanged in the mutant mice (Figure 3E). Changes in energy expenditure in Alk7 mutant mice were not due to ‘browning’ of subcutaneous adipose tissue, as expression of brown adipose tissue (BAT) marker genes Ucp1 and Elovl3 was not increased in the subcutaneous fat of the mutants (Figure 3—figure supplement 1A,B). Moreover, the browning effects of the β3-AR-specific agonist CL316243 were comparable in subcutaneous adipose tissue of wild type and Alk7 knock-out mice (Figure 3—figure supplement 1C,D). Neither was expression of BAT markers elevated in the BAT of Alk7 mutant mice (data not shown). Global and fat-specific Alk7 knock-out mice showed higher physical activity than wild type controls after a high fat diet (Figure 3F,G). However, it was recently reported that changes in activity do not drive changes in energy expenditure in groups of mice below thermoneutrality (Virtue et al., 2012). We hypothesized that increased energy expenditure in Alk7 mutant mice on a high fat diet may be due to higher basal metabolic rate, and investigated adipose tissue mitochondria biogenesis and function, which are impaired by chronic nutrient overload in rodents and humans (Heilbronn et al., 2007; Rong et al., 2007; Sutherland et al., 2008). Mitochondria biogenesis, as measured by mitochondrial DNA content (Figure 4A,B), citrate synthase activity (Figure 4C,D), and ATP content (Figure 4E,F), was significantly increased in adipose tissue of both global and fat-specific Alk7 knock-out mice on a high fat diet compared to controls. In addition, several markers of mitochondrial biogenesis and function were also significantly upregulated in the mutants, including PGC-1α, a master regulator of mitochondrial biogenesis (Wu et al., 1999), mitochondrial uncoupling protein 3 (UCP-3), cytochrome C, and Hadhb, a key mitochondrial enzyme for β-oxidation of long chain fatty acids (Middleton, 1994) (Figure 4G,H). In line with these changes, fatty acid oxidation activity was enhanced in the adipose tissue of global and fat-specific Alk7 mutant mice (Figure 4I,J). These results suggest that resistance to diet-induced obesity in Alk7 mutant mice is due to increased energy expenditure and enhanced mitochondrial function and lipid oxidation in adipose tissue.
Activation of β-ARs by catecholamines is the major regulatory pathway of fat mobilization during starvation and exercise. Mice lacking all three types of β-ARs are massively obese on a high fat diet without an increase in food intake (Bachman et al., 2002). Conversely, β-agonist treatment induces mitochondria biogenesis in adipose tissue and reduces fat mass (Ghorbani et al., 1997), resembling the phenotype observed in Alk7 mutant mice. β-AR-dependent fat mobilization is severely impaired during a high fat diet, allowing fat accumulation in adipose tissue, but the underlying mechanisms of catecholamine resistance have not been clarified (Reynisdottir et al., 1994; Jocken et al., 2008). We investigated whether ALK7 could play a role in the catecholamine sensitivity of adipose tissue under a low caloric diet and after nutrient overload. Under a chow diet, injection of the β3-AR-specific agonist CL316243 enhanced lipolysis, as measured by free fatty acid release, significantly more in fat-specific Alk7 knock-out mice than in wild type controls (Figure 5A). After 16 weeks on a high fat diet, global and fat-specific Alk7 knock-out mice also displayed elevated lipolysis compared to controls under both basal conditions and following β3-AR stimulation (Figure 5B,C). On the other hand, we detected no change in basal or agonist-stimulated lipolysis in brain-specific Alk7 knock-out mice (Figure 5D). As levels of epinephrine and norepinephrine were not significantly altered in the adipose tissue of Alk7 knock-out mice (Figure 5—figure supplement 1), these data suggested enhanced catecholamine sensitivity in adipose tissue lacking ALK7. In agreement with this, the levels of Adrb1 and Adrb3 mRNAs were significantly protected in Alk7 knock-out mice after 16 weeks on a high fat diet, but were barely detectable in the adipose tissue of control mice (Figure 5E,F). In addition, expression of the negative regulator of adrenergic signaling Rgs2, an inhibitor of adenylate cyclase, was elevated after a high fat diet in the adipose tissue of wild type mice but not in Alk7 knock-out mice (Figure 5G) or fat-specific Alk7 knock-out mice (Figure 5H,I). Adrb1 and Adrb3 mRNA levels were also significantly higher in fat-specific Alk7 knock-outs compared to controls after a high fat diet (Figure 5H,I). In line with enhanced adrenergic signaling, we observed increased levels of total and phosphorylated hormone-sensitive lipase (HSL), a major target of the β-adrenergic pathway in adipocytes, and phosphorylated PKA substrates in the adipose tissue of Alk7 knock-out mice after 16 weeks on a high fat diet compared to wild type controls (Figure 5J,K). Moreover, norepinephrine injection induced a more pronounced increase in PKA activity in the adipose tissue of Alk7 knock-out mice than in control mice (Figure 5L). Together, these data suggest that cell-autonomous ALK7 signaling in adipose tissue suppresses catecholamine sensitivity and β-adrenergic signaling under a high fat diet.
The enhanced catecholamine sensitivity of adipose tissue in Alk7 mutant mice prompted us to investigate the acute effects of ALK7 signaling on β-AR expression and adrenergic signaling in cultured adipocyte cells derived by differentiation from mouse embryonic fibroblasts (MEFs). Stimulation of wild type adipocytes with the ALK7 ligand activin B reduced expression of Adrb2 and Adrb3 mRNAs as well as mRNA for the β-adrenergic target gene Hsl (Figure 6A). Activin B had no effect on adipocytes derived from Alk7 knock-out MEFs (Figure 6B), indicating that its effects on adipocyte gene expression were mediated by ALK7. Activin B also downregulated expression of mRNA encoding PPARγ, a master regulator of adipogenesis (Figure 6A). However, the effects of activin B on adipocyte Adrb mRNA expression are likely to be independent of PPARγ, since inhibition of PPARγ had no significant effect on Adrb3 mRNA levels and activin B could suppress Adrb3 mRNA expression even in the presence of the PPARγ inhibitor or the PPARγ agonist rosiglitazone (Figure 6—figure supplement 1). Conversely, the related ligand activin A, which does not stimulate ALK7 signaling, enhanced adipocyte PPARγ mRNA expression but had no significant effect on Adrb2, Adrb3, and Hsl mRNA levels in wild type adipocytes (Figure 6C). Expression of Adrb2, Adrb3, and Hsl mRNAs was also significantly reduced in Alk7 knock-out adipocytes following ALK7 adenovirus-mediated overexpression (Figure 6D), which leads to ligand-independent receptor activation, showing that ALK7 is sufficient to suppress β-AR expression and signaling in adipocytes. In addition, activin B antagonized the stimulatory effects of the β3-AR agonist on the phosphorylation of HSL, perilipin, and PKA substrates in wild type adipocytes (Figure 6E,F). In line with these findings, activation of ALK7 signaling by either ligand or adenovirus-mediated overexpression suppressed β-agonist induced lipolysis in wild type adipocytes (Figure 6G,H). Interestingly, both activin B and adenovirus-mediated ALK7 overexpression also suppressed β-agonist stimulated lipolysis in human adipocytes (Figure 6I,J). Together, these results indicate that acute activation of ALK7 is sufficient to suppress β-adrenergic signaling in both mouse and human adipocytes.
Finally, we sought to determine whether acute blockade of ALK7 signaling in adult mice, by-passing possible developmental effects, could also enhance catecholamine sensitivity in adipose tissue and ameliorate diet-induced obesity. To this end, we devised a chemical-genetic approach to acutely inhibit the ALK7 kinase in adult mice using synthetic ATP analogues (Bishop et al., 1998, 2001). An analogue-sensitive kinase allele of Alk7 (termed Alk7ASKA) was engineered by mutation of two residues in the active site of the ALK7 kinase. Substitution of the ‘gatekeeper’ residue Ser270 with Gly creates an extra pocket in the ALK7 active site, which can be further expanded by mutating the adjacent residue Leu250 to Val. As assessed in transfected cells, the mutations had no effect per se on ligand-mediated signaling, but rendered the mutant receptor sensitive to inhibition by ATP competitive inhibitors, such as 2NaPP1 (Figure 7—figure supplement 1). 2NaPP1 treatment did not affect signaling by the wild type ALK7 receptor (Figure 7—figure supplement 1). Knock-in mice were generated carrying the two mutations in the Alk7 locus (Figure 7—figure supplement 2). Alk7ASKA mice developed normally, and displayed normal growth and normal fasting insulinemia and glycemia (data not shown). Activin B signaling was suppressed by 1NaPP1 (an isomer of 2NaPP1 with established in vivo stability [Savitt et al., 2012]) in adipocytes derived from Alk7ASKA homozygote mice but not from wild type controls (Figure 7A,B). Residual activin B activity in Alk7ASKA adipocytes treated with 1NaPP1 was likely due to expression of the related receptor ALK4, which can also respond to activin B by activating Smad3. We subjected cohorts of 2-month-old Alk7ASKA homozygote and wild type mice to a high fat diet together with twice daily injection of 30 mg/kg 1NaPP1 or vehicle, and monitored their weight daily during a period of 2 weeks. Alk7ASKA and wild type mice gained weight at the same rate on a high fat diet, increasing by approximately 4 g by the end of the second week (Figure 7C,D). There was no weight gain on a chow diet for either genotype (Figure 7C,D). Injection of 1NaPP1 significantly reduced the weight gain rate in Alk7ASKA mice, which on average increased by only 1.6 g after 2 weeks on a high fat diet (Figure 7C). 1NaPP1 had no effect on wild type mice (Figure 7D). These results indicate that acute disruption of ALK7 signaling can protect adult mice from diet-induced obesity. Analogue treatment significantly reduced fat accumulation in epididymal and retroperitoneal adipose tissue depots in Alk7ASKA but not wild type mice (Figure 7E,F). Adipocyte cell size was also significantly reduced in Alk7ASKA mice treated with 1NaPP1 compared to vehicle (Figure 7G,H). We also observed enhanced induction of lipolysis by the β3-AR-specific agonist CL316243 in adipose tissue biopsies extracted from Alk7ASKA mice that had been treated with 1NaPP1 (Figure 8A). Moreover, treatment with 1NaPP1 increased the levels of Adrb3 mRNA in epididymal and retroperitoneal adipose tissue of Alk7ASKA mice on a high fat diet (Figure 8B). In line with enhanced catecholamine sensitivity, 1NaPP1 treatment attenuated the suppressive effects of a high fat diet on adrenergic signaling in adipose tissue of Alk7ASKA mice, as assessed by the levels of phosphorylated HSL and PKA substrates (Figure 8C–E). Together, these data indicated that acute disruption of ALK7 signaling in adult mice can uncouple nutrient overload from catecholamine resistance in adipose tissue, resulting in reduced fat accumulation and decreased weight gain on a high fat diet.
In mice and humans, nutrient overload induces catecholamine resistance in adipose tissue, thereby suppressing lipolysis and fatty acid oxidation, and enhancing fat accumulation. This is an efficient adaptive mechanism for energy storage during times of abundant food supply, enhancing survival upon starvation. In the modern industrialized world, however, the effortless availability of foods with high caloric content, together with reduced physical activity, has resulted in an obesity pandemic. Remarkably, the mechanisms linking nutrient overload to catecholamine resistance in adipose tissue are not well understood. Clarifying these mechanisms is important, as selective enhancement of catecholamine sensitivity and β-adrenergic signaling in adipose tissue could be useful in the treatment of obesity. Obesity is thought to induce catecholamine resistance in adipose tissue by downregulating β-AR expression and interfering with downstream β-adrenergic signaling pathways, such as PKA activity (Reynisdottir et al., 1994; Arner, 1999; Jocken et al., 2008). Our results demonstrate that ALK7 signaling contributes to catecholamine resistance by limiting both β-AR expression and signaling in adipocytes during a high fat diet. Signaling pathways are known to be regulated by negative feedback loops that limit intracellular responses upon sustained stimulation. Adrenergic signaling in adipose tissue self-attenuates under a high fat diet through PKA-mediated upregulation of Rgs2 (Song et al., 2010). Interestingly, a mutation in the Rgs2 promoter that increases Rgs2 expression has been shown to enhance susceptibility to metabolic syndrome in humans (Freson et al., 2007). However, it is unclear how elevated levels of Rgs2 can be sustained in adipose tissue during persistent catecholamine resistance. In our studies, disruption of ALK7 in adipose tissue largely prevented the upregulation of Rgs2 under a high fat diet, suggesting that ALK7 signaling may contribute to the maintenance of diet-induced Rgs2 expression, possibly by cooperating with intermediate regulators, such as Crtc3 (Song et al., 2010).
Our studies in fat-specific Alk7 knock-out mice and Alk7ASKA knock-in mice demonstrate that ALK7 functions cell-autonomously and homeostatically in adult adipocytes to regulate catecholamine sensitivity in response to the diet. Adipocytes lacking ALK7 retain significant levels of β-AR expression and adrenergic signaling, allowing sustained lipid catabolism and increased energy expenditure. Although such a short-circuit would clearly be maladaptive upon starvation, it offers a therapeutic opportunity for the treatment of obesity. The fact that activin B and adenovirus-mediated ALK7 overexpression suppressed β-agonist stimulated lipolysis in human adipocytes suggests functional conservation of the ALK7 signaling pathway in human diet-induced obesity. A high fat diet and obesity increase adipocyte expression of the two main ALK7 ligands activin B and GDF-3 (Witthuhn and Bernlohr, 2001; Sjöholm et al., 2006; Hoggard et al., 2009), suggesting enhanced ALK7 signaling in obesity. In line with this, diet-induced obesity elevates the level of activated phospho-Smad3 in mouse adipose tissue (Yadav et al., 2011). Mouse and human Alk7 mRNA expression is highest in adipose tissue, but undetectable in heart, liver or muscle (Kang and Reddi, 1996; Rydén et al., 1996; Carlsson et al., 2009; Murakami et al., 2012). Thus, modulation of ALK7 signaling may offer an alternative approach to regulate catecholamine sensitivity and β-adrenergic signaling specifically and selectively in adipose tissue. We propose that ALK7 represents a novel link between nutrient overload and catecholamine resistance in adipose tissue, and suggest that strategies to suppress ALK7 signaling may be beneficial to combat human obesity.
Mice were housed under a 12 hr light–dark cycle, and fed a standard chow diet or a high fat diet (HFD, 60% of calorie from fat; ResearchDiet). The following transgenic mouse lines were used for experiments: Alk7 knock-out (Jörnvall et al., 2004), Ap2CRE (He et al., 2003), NestinCRE (Tronche et al., 1999), Alk7fx conditional knock-out (this study), and Alk7ASKA knock-in (this study). The Alk7fx conditional knock-out allele was generated by inserting loxP sites flanking exons 5 and 6 (Figure 1—figure supplement 1). Fat-specific knock-out lines were generated by crossing Alk7fx or Alk7fx/ to Ap2CRE. Brain-specific knock-out lines were generated by crossing Alk7fx to NestinCRE. The Alk7ASKA knock-in allele was generated by introducing L250V and S270G mutations into the Alk7 gene exons 4 and 5, respectively (Figure 7—figure supplement 2). Targeting vectors were generated using BAC clones from the C57BL/6J RPCIB-731 BAC library and transfected into the TaconicArtemis C57BL/6N Tac ES cell line. Gene-targeted mice were generated at TaconicArtemis (Germany) by standard methods. Animal experiments were approved by Stockholm North Ethical Committee for Animal Research.
Fat and lean mass were measured using a body composition analyzer (EchoMRI Medical System, Houston, TX, USA). Indirect calorimetry, food intake, and locomotor activity were determined using a comprehensive laboratory animal monitoring system (Columbus Instruments, Columbus, OH, USA) as previously described (Chibalin et al., 2008). Mice were housed individually with ad libitum access to a high fat diet and water. Mice were acclimatized to the metabolic cages for 24 hr prior to a 24 hr period of automated recordings. Oxygen consumption (VO2) and CO2 production were determined by an open-circuit Oxymax. Accumulated VO2 was presented in l/kg/day and energy expenditure was reported as heat production divided by kilograms of body weight (kcal/kg/day). Ambulatory locomotor activity (XAMB) was measured by consecutive beam breaks in adjacent beams during a 24 hr period and presented as counts/min.
Alk7ASKA and wild type mice (8 weeks old) kept on a chow diet were individually caged for 1 week, then switched to HFD or kept on a chow diet. 1NAPP1 was freshly formulated in PEG400 at a concentration of 12.5 mg/ml before use. Twice daily (9:30 AM and 5:30 PM, respectively) mice on HFD received subcutaneous injections of vehicle or 1NAPP1 (50 mg/kg/day).
Glucose tolerance tests were performed on animals kept on chow or a high fat diet after overnight fasting. Blood glucose was measured by tail tip bleeding using a glucometer (Accutrend; Roche, Sweden) at the indicated time points before and after intraperitoneal injection of 2 g/kg (body weight) glucose. Serum insulin was measured from tail blood with an ultrasensitive mouse insulin ELISA kit (Mercodia, Sweden). For the insulin tolerance test, mice were fasted for 3 hr, then injected intraperitoneally with 1.5 IU/kg recombinant human insulin (Humulin R; Lilly, Sweden). Glucose levels were determined at the indicated time points as above.
Fresh tissue samples were fixed in 10% formalin, dehydrated, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Photographs of hematoxylin and eosin stained cross-section slides were taken with a light microscope. Areas of individual adipocytes were measured with ImageJ software (National Institutes of Health) and used for quantification of cell size.
For in vivo lipolysis, mouse tail blood was taken from non-fasted mice for measurement of serum free fatty acids before and after intraperitoneal injection of the β3-AR-specific agonist CL316243 (Sigma-Aldrich, Sweden) (100 μg/kg body weight) at the indicated times (20 min or 40 min). For ex vivo lipolysis, epididymal fat pieces weighing about 20 mg were incubated in Krebs–Ringer Bicarbonate Buffer (KRBH) containing 1% fatty acid-free BSA (Sigma-Aldrich) and glucose (2.5 mM). The samples were treated with either vehicle or CL316243 (1 μM) for 2 hr at 37°C with mild shaking at 150 rpm. After incubation, glycerol release was measured using a free glycerol reagent (Sigma-Aldrich), and normalized to the total amount of protein in adipose tissue samples. For in vitro lipolysis in MEF-derived or human adipocytes, differentiated adipocytes were washed with KRBH and treated with either vehicle, CL316243 (1 μM), Norepinephrine (1 μM), or isoproterenol (1 μM) for 3 hr, and glycerol release was measured as before.
Primary adipocytes were isolated from epididymal adipose tissue after collagenase II (1 mg/ml, Sigma-Aldrich) digestion, and were incubated with KRBH containing 1% fatty acid-free BSA (Sigma-Aldrich), glucose (2.5 mM), palmitic acid (100 μM), and 3H palmitic acid (0.5 μCi/ml). For normalization of counts by total protein, an aliquot of adipocytes was snap frozen without BSA and 3H palmitic acid incubation. After incubation for 5 hr at 37°C with shaking at 150 rpm, an equal volume of chloroform was added. After chloroform separation, 100 μl of the aqueous phase was further mixed with 900 μl 10% activated charcoal slurry thoroughly by shaking for 30 min. The mixture was subsequently centrifuged at maximum speed at room temperature for 10 min, and 100–200 μl supernatant was taken for assessment of 3H counts.
MEFs were prepared from 13.5-day wild type and Alk7 mutant embryos, and differentiated into adipocytes according to a standard protocol (Zhang et al., 2009). Briefly, MEF cells were plated at about 50–70% confluence on 0.1% gelatin-coated dishes, cultured in DMEM, supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, MEM Non-Essential Amino Acids Solution (Invitrogen, Sweden), 0.5 mM 2-mercaptoethanol, and 100 U/ml penicillin and streptomycin (MEF medium). MEF monolayers were allowed to grow to confluence before initiation of adipogenesis. Adipogenesis was induced by incubation in MEF medium supplemented with 10 μg/ml insulin, 0.5 mM IBMX, 1 μM dexamethasone, and 0.5 μM rosiglitazone (adipocyte differentiation medium). After 2 days, the medium was changed to MEF medium supplemented with only 10 μg/ml insulin and 0.5 μM rosiglitazone (adipocyte maintenance medium), and then changed again every 2 days until full differentiation (i.e., day 8–10). Human preadipocytes were purchased from Lonza Biologics and differentiated into adipocytes according to the manufacturer's instructions. For activin B or activin A treatment, cells were incubated with 100 ng/ml activin B or activin A (R&D; Systems, UK) in adipocyte maintenance medium for 48 hr before lipolysis assay or, alternatively, harvested for extraction of RNA and proteins. PPARγ agonist rosiglitazone was used at 0.5 μM; PPARγ antagonist T0070907 at 1 μM. Adenovirus particles were produced and amplified in HEK293 cells as previously described (Fujii et al., 1999). Adipocytes were infected with Adeno-ALK7 or Adeno-LacZ at 2.0 multiplicity of infection (MOI) for 48 hr before lipolysis assay or extraction of RNA. For assessment of nuclear p-Smad3, MEF-derived adipocytes were incubated for 150 min with 2 μM 1NaPP1 or vehicle (DMSO) then treated for 40 min with 20 ng/ml activin B, or left untreated, and fixed with 4% paraformaldehyde. Adipocytes were identified by BODIPY 493/503 staining and p-Smad3 was assessed by immunocytochemistry with antibodies from Epitomics. DAPI was used for nuclear staining. Images were obtained with a Zeiss laser confocal microscope. The intensity of nuclear p-Smad3 was determined using Zen software (Zeiss, Germany) in adipocytes from three random fields in three different wells per condition. The number of cells displaying nuclear p-Smad3 intensity above an arbitrary threshold was determined in each field, added up for each well, and averaged across the three wells of each condition. All values were then normalized to the number of responding cells in cultures of wild type adipocytes stimulated with activin B (set to 100). The experiment was repeated three times and the results were averaged across the three experiments.
Serum triglyceride (Infinity triglyceride reagent; Thermo DMA), free fatty acids (Free Fatty Acids Half Micro Test; Roche), leptin (mouse leptin ELISA; Abcam, UK), insulin (Ultrasensitive mouse insulin ELISA; Mercodia), and tissue ATP contents (ATPLite; PerkinElmer) were measured with commercial kits according to the manufacturer's instructions. For quantification of mitochondria DNA, total adipose tissue DNA was extracted with a DNeasy kit (Qiagen, Sweden) and 1 ng was used for Q-PCR quantification of the copy number for mitochondrial encoded gene cytochrome B. This was normalized to the copy number of the nuclear gene H19. Citrate synthase activity was measured as described (Srere et al., 1963) in tissue samples homogenized in RIPA buffer. Epinephrine and norepinephrine were measured in adipose tissue extracts by a commercial ELISA kit according to the manufacturer's instructions (Labor Diagnostika Nord, Sweden). A PKA activity assay was performed with PepTag Non-Radioactive cAMP-Dependent Protein Kinase Assay (Promega, Sweden).
For isolation of adipocyte and stromal-vascular fractions (SVF), tissues were dissected from epididymal depots of 8-week-old mice, minced with forceps in PBS, and washed three times with 0.1% BSA KRBH. Digestion was carried out for 90–120 min in 2% BSA KRBH containing 0.2 mg/ml collagenase II (Sigma-Aldrich) with constant agitation. Digested tissue was filtered through 250 μm nylon mesh and centrifuged for 10 min at 1000 rpm (200×g) to separate floating adipocytes. The supernatant and the pellet were further centrifuged for 10 min at 1500 rpm (240×g). The resulting pellet (SVF) and the adipocytes were resuspended in lysis buffer and kept at −80°C. ‘Browning’ of subcutaneous adipose tissue was induced by chronic treatment with CL316243. A number of 12–16-week-old mice were injected daily intraperitoneally with either 1 mg/kg CL316243 (Sigma) or PBS only (vehicle) for 7 days. Inguinal subcutaneous adipose tissue was isolated from these mice. Total RNA from tissues or cells was isolated with an RNAeasy kit (Qiagen) according to the manufacturer's instructions. Isolated RNA samples were digested with DNase prior to reverse transcription with Superscript II (Invitrogen). Q-PCR of cDNA samples was performed on a ABI StepOne Plus instrument (Applied Biosystems, Sweden) using SYBR Green master mix (Applied Biosystems) and primers as indicated in Supplementary file 1.
The R4-2 cell line is a derivative of MvLu1 mink lung epithelial cells that expresses low levels of type 1 TGF-β receptors (Andersson et al., 2008). R4-2 cells were cultured in 24-well plates in DMEM medium supplemented with 10% serum and antibiotics. They were transfected using Lipofectamine 2000 (Invitrogen) with expression plasmids carrying wild type or Aska variants of the rat Alk7 cDNA, the Smad3-dependent luciferase reporter plasmid CAGA-Luc (Dennler et al., 1998), and a Renilla plasmid for normalization. At 24 hr after transfection, cells were stimulated with 25 ng/ml activin B together with 1 μM 2NaPP1 (solubilized in DMSO) or DMSO only (vehicle). Then 24 hr after stimulation, luciferase activity was analyzed using the Dual-Luciferase Reporter Assay System (Promega) in a 1450 Microbeta Jet counter (Wallac). For assays of p-Smad2 by Western blotting, cells were treated 48 hr after transfection with 1 μM 2NaPP1 for 3 hr prior to addition of 25 ng/ml activin B for an additional hour. Monolayers were then processed for Western blotting as described below.
Protein extraction and Western blotting were performed according to standard protocols. Briefly, snap-frozen adipose tissue or cell samples were homogenized in ice-cold RIPA buffer (50 mM Tris–HCl pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM sodium chloride, 1 mM EDTA) containing 1 mM sodium orthovanadate, 1 mM sodium fluoride, and proteinase inhibitor cocktail (Roche), and centrifuged at 13,000×g for 15 min to collect supernatants. Supernatants (30 μg protein) were used for reducing SDS PAGE and Western blotting. Primary antibodies against p-HSL, HSL, p-PKA substrates, p-Perilipin, p-Smad2, β-actin, and α-tubulin (Cell Signaling, Sweden) were used at 1:2000 dilution. The levels of target proteins were quantified by the intensity of Western blot bands using ImageJ software (National Institutes of Health).
Statistical significance was determined by using unpaired two-tailed or one-tailed Student's t tests and one-way ANOVA. Differences were considered significant at a p value less than 0.05. Quantified data are presented as mean ± SEM.
Growth/differentiation factor 3 signals through ALK7 and regulates accumulation of adipose tissue and diet-induced obesityProceedings of the National Academy of Sciences of USA 105:7252–7256.https://doi.org/10.1073/pnas.0800272105
Challenges in β(3)-adrenoceptor agonist drug developmentTherapeutic Advances in Endocrinology and Metabolism 2:59–64.https://doi.org/10.1177/2042018811398517
Activin B receptor ALK7 is a negative regulator of pancreatic beta-cell functionProceedings of the National Academy of Sciences of USA 105:7246–7251.https://doi.org/10.1073/pnas.0801285105
ALK7 expression is specific for adipose tissue, reduced in obesity and correlates to factors implicated in metabolic diseaseBiochemical and Biophysical Research Communications 382:309–314.https://doi.org/10.1016/j.bbrc.2009.03.014
-391 C to G substitution in the regulator of G-protein signalling-2 promoter increases susceptibility to the metabolic syndrome in white European men: consistency between molecular and epidemiological studiesJournal of Hypertension 25:117–125.https://doi.org/10.1097/HJH.0b013e3280109c6c
Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiationMolecular Biology of the Cell 10:3801–3813.https://doi.org/10.1091/mbc.10.11.3801
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscleProceedings of the National Academy of Sciences of USA 100:15712–15717.https://doi.org/10.1073/pnas.2536828100
Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjectsThe Journal of Clinical Endocrinology and Metabolism 92:1467–1473.https://doi.org/10.1210/jc.2006-2210
Inhibin betaB expression in murine adipose tissue and its regulation by leptin, insulin and dexamethasoneJournal of Molecular Endocrinology 43:171–177.https://doi.org/10.1677/JME-09-0046
ALK7, a receptor for nodal, is dispensable for embryogenesis and left-right patterning in the mouseMolecular and Cellular Biology 24:9383–9389.https://doi.org/10.1128/MCB.24.21.9383-9389.2004
Identification and cloning of a novel type I serine/threonine kinase receptor of the TGF-beta/BMP superfamily in rat prostateBiochemistry and Molecular Biology International 40:993–1001.
The mitochondrial long-chain trifunctional enzyme: 2-enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase and 3-oxoacyl-CoA thiolaseBiochemical Society Transactions 22:427–431.
Expression of activin receptor-like kinase 7 in adipose tissuesBiochemical Genetics 51:202–210.https://doi.org/10.1007/s10528-012-9555-8
Multiple lipolysis defects in the insulin resistance (metabolic) syndromeThe Journal of Clinical Investigation 93:2590–2599.https://doi.org/10.1172/JCI117271
A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous systemThe Journal of Biological Chemistry 271:30603–30609.https://doi.org/10.1074/jbc.271.48.30603
Neuroendocrine control of female reproductive function by the activin receptor ALK7The FASEB Journal 26:4966–4976.https://doi.org/10.1096/fj.11-199059
The expression of inhibin beta B is high in human adipocytes, reduced by weight loss, and correlates to factors implicated in metabolic diseaseBiochemical and Biophysical Research Communications 344:1308–1314.https://doi.org/10.1016/j.bbrc.2006.04.030
The citrate condensing enzyme of pigeon breast muscle and moth flight muscleActa Chemica Scandinavica 17:S129–S134.https://doi.org/10.3891/acta.chem.scand.17s-0129
Time course of high-fat diet-induced reductions in adipose tissue mitochondrial proteins: potential mechanisms and the relationship to glucose intoleranceAmerican Journal of Physiology Endocrinology and Metabolism 295:E1076–E1083.https://doi.org/10.1152/ajpendo.90408.2008
Activin isoforms signal through type I receptor serine/threonine kinase ALK7Molecular and Cellular Endocrinology 220:59–65.https://doi.org/10.1016/j.mce.2004.03.009
Adipose-specific deletion of autophagy-related gene 7 (atg7) in mice reveals a role in adipogenesisProceedings of the National Academy of Sciences of USA 106:19860–19865.https://doi.org/10.1073/pnas.0906048106
Peter TontonozReviewing Editor; University of California, Los Angeles, United States
eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see review process). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.
Thank you for sending your work entitled "Adipocyte ALK7 links nutrient overload to catecholamine resistance in obesity" for consideration at eLife. Your article has been favorably evaluated by Randy Schekman (Senior editor) and 3 reviewers, two of whom are members of our Board of Reviewing Editors.
The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.
The reviewers were in agreement that the work was exciting and potentially of interest to the readers of eLife. However, several major issues were identified that need to be addressed in order to strengthen the conclusions drawn. In particular, all three reviewers raised concerns about the animal models and identified a need for additional metabolic characterization and analysis of thermogenesis.
1) Mouse models. The authors cannot definitively conclude that the effects are specific to adipose tissue with the models used. First, the Fabp4 promoter also drives expression in non-adipocyte cells, including myeloid cells. Second, the authors make use of a whole body heterozygote knockout mouse for their tissue-specific loss-of-function studies. In their previous work, the authors demonstrated that ALK7 ablation causes beta cell dysfunction and metabolic disease. To address these concerns, the authors should examine deletion of ALK7 in macrophages and brain and address whether there is an intrinsic effect of ALK7 deletion on macrophage M1/M2 polarization. The authors should also soften the conclusions that the effects are adipocyte intrinsic, as this statement cannot be adequately supported using the Ap2cre model.
2) Energy balance. The authors should address whether the ALK7 depletion or inhibition actually enhances browning of subcutaneous adipose tissue. Chronic administration of the CL compound or cold exposure yields increasing numbers of brite/beige adipocytes in normal mice. The authors should test whether "browning" is enhanced under such protocols. The data for expression of UCP1, Cidea and other brown fat markers should also be included for subcutaneous WAT and BAT.
3) Metabolic characterization. Previous work by this group demonstrated that Alk7-/- mice have a metabolic dysfunction but the current manuscript does not include any data testing whether glucose metabolism or insulin sensitivity is perturbed in the new Alk7 mouse models. The authors should perform glucose tolerance tests, insulin tolerance tests, and fasting glucose and insulin measurements.https://doi.org/10.7554/eLife.03245.020
- Carlos F Ibanez
- Carlos F Ibanez
- Carlos F Ibanez
- Carlos F Ibanez
- Carlos F Ibanez
- Carlos F Ibanez
- Carlos F Ibanez
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
We thank Peter Arner, Mikael Ryden, Juleen Zierath, and Anna Krook for discussion; Annica Ho, Olov Andersson, and Philippe Bertolino for preliminary Aska experiments; Peter ten Dijke for reagents; and Annika Andersson and Berit Engst for technical assistance. This work was supported by grants from the European Research Council, Swedish Research Council, Strategic Research Program in Diabetes of Karolinska Institutet, Swedish Cancer Society, Knut and Alice Wallenberg Foundation (Wallenberg Scholars Program), and the National University of Singapore.
Animal experimentation: Animal experiments were approved by the Stockholm's North Ethical Committee for Animal Research as per ethical protocols N111/14, N115/14 and N36/14.
- Peter Tontonoz, Reviewing Editor, University of California, Los Angeles, United States
- Received: May 4, 2014
- Accepted: August 2, 2014
- Version of Record published: August 26, 2014 (version 1)
© 2014, Guo et al
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.